Asia Pacific Investigational New Drug Cdmo Market Size & Outlook
Asia Pacific investigational new drug cdmo market, 2018-2028 (US$M)
Related Markets
Asia Pacific investigational new drug cdmo market highlights
- The Asia Pacific investigational new drug cdmo market generated a revenue of USD 1,060.2 million in 2021.
- The market is expected to grow at a CAGR of 7.7% from 2022 to 2028.
- In terms of segment, small molecule was the largest revenue generating product in 2021.
- Large Molecule is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2022 to 2028.
Asia Pacific data book summary
| Market revenue in 2021 | USD 1,060.2 million |
| Market revenue in 2028 | USD 1,780.8 million |
| Growth rate | 7.7% (CAGR from 2021 to 2028) |
| Largest segment | Small molecule |
| Fastest growing segment | Large Molecule |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule, Large Molecule |
| Key market players worldwide | Labcorp Holdings Inc, Charles River Laboratories International Inc, Cambrex, IQVIA Holdings Inc, Syneos Health, Lonza Group Ltd, Catalent Inc, Recipharm, Siegfried Holding AG, Thermo Fisher Scientific Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 24.8% of the global investigational new drug cdmo market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2028.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,780.8 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Investigational New Drug CDMO Market Scope
Investigational New Drug CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific investigational new drug cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to investigational new drug cdmo market will help companies and investors design strategic landscapes.
Small molecule was the largest segment with a revenue share of 88.79% in 2021. Horizon Databook has segmented the Asia Pacific investigational new drug cdmo market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2028.
- Asia Pacific Investigational New Drug CDMO Product Outlook (Revenue, USD Million, 2018-2028)
- Small Molecule
- Large Molecule
- Asia Pacific Investigational New Drug CDMO Services Outlook (Revenue, USD Million, 2018-2028)
- Contract Development
- Small Molecule
- Bioanalysis and DMPK studies
- Toxicology Testing
- Pathology and safety pharmacology studies
- Drug substance synthetic route development
- Drug substance process development
- Form selection crystallization process development
- Scale-up of drug substance
- Preformulation
- Preclinical formulation selection
- First in Man Formulation/ Process Development
- Analytical method development / validation
- Release testing of drug substance and drug product
- Work up Purification Steps
- Telescoping & Process Refining
- Initial Optimization
- Formal stability of drug substance and drug product
- Large Molecule
- Cell Line development
- Process Development
- Upstream
- Microbial
- Mammalian
- Others
- Downstream
- MABs
- Recombinant proteins
- Others
- Upstream
- Small Molecule
- Contract Manufacturing
- Small Molecule
- Oral Solids
- Liquid and Semi-solids
- Injectables
- Others
- Large Molecule
- MABs
- Recombinant proteins
- Others
- Small Molecule
- Contract Development
- Asia Pacific Investigational New Drug CDMO End Use Outlook (Revenue, USD Million, 2018-2028)
- Pharmaceutical Companies
- Small
- Medium
- Large
- Biotech Companies
- Others
- Pharmaceutical Companies
Reasons to subscribe to Asia Pacific investigational new drug cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific investigational new drug cdmo market databook
-
Our clientele includes a mix of investigational new drug cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific investigational new drug cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific investigational new drug cdmo market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific investigational new drug cdmo market size, by country, 2018-2028 (US$M)
Asia Pacific Investigational New Drug CDMO Market Outlook Share, 2021 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
